GBM Clinical Trial
Official title:
A Randomized, Control, Open-label, Multicenter, Phase II/III Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients
The purpose of phase II/III study: Determining the Overall Survival(OS)of Chlorogenic acid for injection comparing to in the advanced Glioblastoma Patients through study completion(an average of 18 months)after the first dose of chlorogenic acid for injection and Lomustine.
Chlorogenic acid (CHA) is a class 1 innovative small molecular natural drug, developed by
Sichuan Jiuzhang Biological Science and Technology Co., Ltd. The mechanism of broad-spectrum
antitumor activity is immunoregulation. After received the clinical trial approval issued by
CFDA, Jiuzhang Biotech successfully finished the phase I clinical studies of CHA for
injection in advanced GBM patients, focus on safety, PK, and preliminary efficacy evaluation.
The results of phase I data showed that CHA had good safety, the main adverse effect was
induration, no other serious adverse effects. PK exhibited that CHA had a rapid metabolism
character (t1/2 = 1-1.5 h). In addition, there were no accumulative side effects for
long-term use. To the investigators' surprise, the preliminary efficacy evaluation was
amazing, there were 1 case CR and 1 case PR. The median OS of grade IV GBM patients was 21.4
months in effective dose group, which was much better than that of the historical reported
data.The purpose of phase II/III study: Determining the Overall Survival(OS)of Chlorogenic
acid for injection comparing to in the advanced Glioblastoma Patients through study
completion(an average of 18 months)after the first dose of chlorogenic acid for injection and
Lomustine .
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06147505 -
Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05076513 -
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
|
Early Phase 1 | |
Recruiting |
NCT04528680 -
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Terminated |
NCT03149575 -
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
|
Phase 3 | |
Completed |
NCT01478178 -
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
|
Phase 1/Phase 2 | |
Terminated |
NCT03119064 -
BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05686798 -
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
|
Phase 1 | |
Terminated |
NCT01205334 -
Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00114309 -
131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
|
Phase 2 | |
Not yet recruiting |
NCT03746288 -
To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)
|
Phase 2 | |
Terminated |
NCT04681677 -
Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab
|
Phase 2 | |
Completed |
NCT01856933 -
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
|
Phase 2 | |
Terminated |
NCT04763031 -
Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT
|
N/A | |
Completed |
NCT00107003 -
GW572016 to Treat Recurrent Malignant Brain Tumors
|
Phase 2 | |
Completed |
NCT03426891 -
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
|
Phase 1 | |
Recruiting |
NCT06092255 -
A Study of SVZ Irradiation With Postoperative Radiotherapy in Patients With GBM.
|
N/A | |
Recruiting |
NCT04115761 -
Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
|
Phase 2 | |
Recruiting |
NCT05954858 -
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
|
N/A | |
Not yet recruiting |
NCT06388733 -
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
|
Phase 3 | |
Recruiting |
NCT02861898 -
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 |